A retrospective single center study was performed to evaluate the safety and efficacy of valacyclovir for prevention of cytomegalovirus (CMV) infection (reactivation) after allogeneic stem cell transplantation (SCT). We compared a group of 31 patients at risk for CMV reactivation (donor, recipient or both seropositive for CMV) who received valacyclovir at an oral dose of 1 g three times a day for CMV prophylaxis with a matched cohort of 31 patients who did not receive the drug or any other form of CMV prophylaxis. Valacyclovir was used as primary prophylaxis in 12 patients and as secondary prophylaxis (after a prior CMV reactivation was effectively treated with either ganciclovir or foscarnet and without CMV antigenemia at the start of valacyclovir) in the remaining 19 patients. The two treatment groups were well matched for the donorrecipient CMV serological status and other pre-transplant characteristics. CMV reactivation was detected by blood antigenemia testing using a commercially available immunofluorescence assay for CMV lower matrix protein pp65 in circulating leukocytes. For primary prophylaxis, 3/12 patients who received valacyclovir reactivated CMV compared to 24/31 patients in the control group (P Ͻ 0.001). For secondary prophylaxis, 5/19 valacyclovir patients reactivated compared to 16/24 control patients (P Ͻ 0.05). Valacyclovir was well tolerated except for infrequent and mild gastrointestinal sideeffects. There was no difference in the incidence of CMV disease in the two groups. Prophylaxis with valacyclovir appears to be safe and efficacious in preventing both primary and secondary CMV reactivation in at-risk patients after allogeneic SCT. Larger prospective randomized studies will be required to confirm these observations. Bone Marrow Transplantation (2001) 28, 265-270.
Hematopoietic stem cell transplantation (SCT), being performed with an increasing frequency for a variety of both malignant and non-malignant conditions, is associated with the occurrence of many infectious complications of which cytomegalovirus (CMV) infection has been the most important.
1,2 CMV infection occurs most frequently after allogeneic SCT with an overall incidence of 50-70%. Patients at risk due to latent virus reactivation are those who themselves, or whose donors have been previously exposed to CMV as determined by antibody seropositivity. A small percentage of patients may acquire CMV from primary exposure or from blood transfusion. The rate of CMV reactivation is greatest in patients developing graft-versushost disease (GVHD) and treated with substantial immunosuppression, especially those receiving corticosteroids. 3 CMV infection encountered after hematopoietic SCT is a strong predictor for the development of CMV disease and is associated with a higher 1 year mortality. 4 The peak incidence of reactivation of CMV in SCT recipients is from 1 to 4 months after transplant.
Considering the severe sequela of CMV disease, several strategies for prevention of CMV have been employed. The earliest use of effective anti-CMV agents was prophylactic, an approach that was especially reasonable at the time when sensitive methods for detection of CMV infection were not available. Current approaches now utilize exquisitely sensitive methods for the detection of CMV replication to indicate preemptive therapy prior to the development of disease. The benefit of preemptive treatment is that patients who never reactivate CMV are spared the potentially serious side-effects of anti-viral medications.
Several commercially available drugs including ganciclovir, foscarnet and high-dose acyclovir have been used in the past for prophylaxis against CMV reactivation. Ganciclovir has been shown to be effective as a prophylactic agent as well as for preemptive treatment. [5] [6] [7] [8] Foscarnet has not been studied as extensively as ganciclovir but has been shown to be efficacious in preventing CMV infection after allogeneic SCT in small series. 9 Although effective, these agents are associated with significant side-effects and entail substantial costs due to the need for intravenous administration and the management of these toxicities. Ganciclovir causes substantial myelosuppression and fos-carnet causes frequent renal insufficiency and electrolyte disturbances, especially in patients receiving other nephrotoxic agents such as cyclosporine/tacrolimus or amphotericin B.
Acyclovir appears to be effective in reducing the incidence of CMV infection but adequate serum levels are required for the drug to be effective. Bioavailability after oral administration of acyclovir is poor, making it impractical for CMV prevention. However, intravenous administration of high doses of the drug (500 mg/m 2 three times a day) has been demonstrated to be effective for CMV prophylaxis after marrow transplantation. [10] [11] [12] Valacyclovir is the oral, L-valyl ester pro-drug of acyclovir and is rapidly and extensively converted to acyclovir after administration. This results in increased bioavailability of acyclovir compared to that achieved with oral acyclovir (three to five times higher). Serum levels and area under the curve (AUC) are comparable to those achieved with intravenous acyclovir. [13] [14] [15] Recent prospective randomized studies using valacyclovir for the prophylactic treatment of CMV infection have shown safety and efficacy in patients with renal transplants and AIDS. [16] [17] [18] [19] However, the benefit of this approach for CMV prophylaxis in SCT recipients has not been reported. We hypothesized that valacyclovir could be useful in the prevention of primary CMV reactivation (drug administered prior to CMV reactivation) or after successful treatment of reactivation with either ganciclovir or foscarnet (secondary prophylaxis) in patients who remain at risk for future reactivation. To evaluate this treatment approach, a retrospective cohort study was performed.
Patients and methods

Patients and eligibility
Demonstration of the efficacy of valacyclovir in prevention of CMV infection by randomized studies in the renal transplant and AIDS patients prompted the use of the drug in the SCT patients at our institution. A chart review was performed of all the adult patients receiving valacyclovir who underwent unmanipulated related or unrelated allogeneic SCT after myeloablative chemotherapy at Vanderbilt University Medical Center and the Nashville Veterans Administration Medical Center between January 1996 and May 2000. Patients were included in the treatment arm if they were CMV antigenemia negative at the time prophylactic valacyclovir was started. Patients who received the drug for indications other than CMV prophylaxis were excluded from the study. Thirty-one patients met the eligibility criteria and were noted as the study group (VG). Valacyclovir was administered orally at a dose of 1 g three times a day with adjustment for renal dysfunction. Twelve of the 31 VG patients received primary prophylaxis and 19 of the 31 patients received the drug for secondary prophylaxis. Thirty-one patients transplanted between September 1993 and May 2000, who did not receive valacyclovir were identified to serve as controls (CG), matched by recipient and donor CMV serological status. The controls were selected 1:1 in a sequential fashion, selecting the most recent transplanted patients first. The controls received acyclovir 400 mg twice a day for prophylaxis against varicella zoster virus commencing at 1 month after transplantation. Sixtyone of the 62 patients (VG and CG) were at risk for CMV reactivation, with recipient, donor or both being seropositive for CMV. One patient in the VG population was not thought to be at risk for CMV reactivation as both the patient and donor were CMV seronegative pre-transplantation. This patient developed CMV infection presumably due to blood transfusion although false negative serology was a possibility and then received valacyclovir for secondary prophylaxis after effective treatment with ganciclovir. This patient was matched with a seronegative recipient who had a seropositive donor.
Detection of CMV reactivation
CMV infection or reactivation is defined as isolation of the virus or evidence of viral replication in the blood or other body fluids in an asymptomatic patient without organ specific abnormalities. CMV disease is defined as isolation of the virus from blood or body fluids in patients with symptoms and/or histological evidence of tissue involvement. All patients at risk for CMV reactivation after allogeneic SCT were tested for blood antigenemia using a commercially available indirect immunoflorescence assay (CMV Brite Turbo Kit; IQ Corporation BV, Groningen, The Netherlands), which detects CMV lower matrix protein pp65 in isolated circulating leukocytes. 20 Patients with one or more positive cells detected by this technique were considered to have reactivated. Testing was performed at least weekly beginning 30 days after SCT and continuing at least to 100 days after transplantation or for as long as they were at risk for reactivation.
Patients who reactivated CMV were treated preemptively with 3 weeks of ganciclovir or foscarnet or until antigenemia was negative. Following successful treatment, weekly surveillance was resumed. The median time of start of valacyclovir in the primary prophylaxis group was day 25 (range 18-40 days) and for secondary prophylaxis was day 65 (range 60-90 days). All patients were included in the analysis even if reactivation occurred within 1 week of starting the drug. Two patients in the VG group who died of pneumonia without concurrent CMV blood antigenemia but with a history of prior CMV reactivation were evaluated for CMV pulmonary infection by post-mortem examination.
Statistical considerations
Percentages were compared by chi-square testing and Fisher's exact testing. The significance of differences in means was determined using Student's t-test. Estimates were calculated by Kaplan-Meier methods, and 95% confidence limits were determined from the standard errors.
Results
Patient characteristics
The details of demographics of the two groups are shown in Tables 1 and 2 . Comparisons of the two groups for parameters that could influence CMV reactivation did not show any significant difference with respect to CMV serological status, age, sex, type of allogeneic SCT, indication for transplant and conditioning regimen prior to transplant (P Ͼ 0.05). There were an equal number of CMV seropositive and seronegative recipients in both the groups. A combination of cyclosporine A and methotrexate was used for GVHD prophylaxis in all 62 patients. The number of patients requiring treatment for GVHD with systemic corticosteroids was statistically similar in both the groups. All patients developing GVHD grade II or higher in either of the groups were treated with systemic corticosteroids at a dose of 2 mg/kg/day as per our institutional guidelines. The median time to follow up was 390 days (range 102- Table 1 Characteristics of the patients in study undergoing allogeneic SCT /l and neutrophils Ͼ0.5 × 10 9 /l was 18.5 (range 8-39 days) and 18 (range 12-30 days) days, respectively, for the VG group compared to 16 (range 8-40 days) and 18 (range 13-27 days) days for the CG group (P Ͼ 0.5).
CMV reactivation
Valacyclovir significantly reduced the incidence of CMV reactivation in both primary and secondary prophylaxis settings. For primary prophylaxis, only three of the 12 patients (25%, 95% CI 9-53%) in the VG group reactivated CMV compared to 24 of the 31 patients (77%, 95% CI 60-89%) Table 2 Characteristics of the patients in study undergoing allogeneic SCT in the CG group (P Ͻ 0.01) (Figure 1 ). All patients who reactivated CMV were treated with ganciclovir, foscarnet or a combination of both agents. One of the three patients in the VG group who reactivated CMV after receiving valacyclovir for primary prophylaxis had clinically resistant CMV infection with persistent antigenemia despite treatment with both ganciclovir and foscarnet and subsequently developed CMV retinitis. The three patients who reactivated CMV after primary prophylaxis were not included in the secondary group as one of these patients had resistant CMV infection/disease, one died due to infectious complications while receiving preemptive therapy with ganciclovir and the other may have been non-compliant. For secondary prophylaxis, of the 24 patients who initially cleared their CMV antigenemia on intravenous ganciclovir or foscarnet, 16 reactivated CMV in the CG group (67%, 95% CI 47-82%) as compared to five of the 19 patients (26%, 95% CI 12-49%) in the VG population (P Ͻ 0.05) (Figure 1 ). Two patients in the secondary VG group who were persistently negative for CMV antigenemia in blood and bronchial washings died of respiratory failure and on autopsy were noted to have viral inclusion bodies in the lung consistent with CMV pneumonia. The negative CMV antigenemia testing in these patients may have been due to low white cell counts (less than 0.5 × 10 9 /l) causing poor yields of buffy coat leukocytes. These patients were considered to have failed valacyclovir for the purposes of analysis.
Secondary
The total number of cycles of preemptive therapy given using ganciclovir was four and 25 in the primary VG and CG groups respectively. Only one cycle of foscarnet was given in the primary VG group compared to three cycles in the CG group. For the secondary VG group, a total of four cycles of ganciclovir and three cycles of foscarnet were given for preemptive therapy as compared to 19 cycles of ganciclovir and 10 cycles of foscarnet in the control group. CMV disease occurred in four patients in the VG group, one in the primary and three in the secondary prophylaxis group of which one patient developed CMV retinitis and three patients developed CMV pneumonia, respectively. Six patients in the CG group developed CMV disease of which four patients developed CMV pneumonia, one developed CMV hepatitis and one CMV retinitis. There was no statistical difference in the incidence of CMV disease between the two groups (P = 0.49). Three of the four patients who developed disease in the VG group died of CMV pneumonia and five of the six patients who developed disease in the CG group died of CMV (P = 0.75). The overall mortality due to all infectious complications was one of 12 (8%, 95% CI 5-29%) in the primary VG group which was not due to CMV disease, four of 19 (21%, 95% CI 17-45%) in the secondary VG group compared to nine of 31 (29%, 95% CI 19-50%) in the CG group (P = 0.12). Due to shorter follow-up in the VG group, the probability of infection was also determined actuarially by KaplanMeier method and did not show any significant difference (P = 0.19).
Discussion
The search for an ideal agent for prevention of CMV after SCT and other organ transplants has been ongoing for many years. Several drugs including ganciclovir, acyclovir and foscarnet have been found to be efficacious in preventing CMV reactivation. However, these drugs are either incompletely active or associated with significant toxicity and substantial cost due to intravenous administration. Thus, use of prophylaxis against CMV has fallen from favor and the standard of care has become CMV surveillance followed by effective preemptive therapy. Valacyclovir satisfies several criteria for an ideal prophylactic agent due to its low toxicity profile, minimal drugdrug interactions, excellent bioavailability after oral administration and modest cost. Valacyclovir has already been shown to be safe and effective in preventing CMV disease in renal transplant and AIDS patients but has not been adequately studied after SCT. Based on these reasons, we began to use valacyclovir for CMV prophylaxis in at-risk patients undergoing SCT.
Studies testing the absolute bioavailability of 1000 mg of valacyclovir compared with 350 mg of intravenous acyclovir given as a 1-h infusion showed the comparable values of AUC. 15 The study by Soul-Lawton et al 15 also demonstrated that 54% of the orally administered valacyclovir is absorbed and 99% of the absorbed drug is rapidly converted to acyclovir to give levels comparable to intravenous acyclovir. Based on the above results, oral valacyclovir should provide levels of acyclovir equivalent to intravenous acyclovir administered three times a day, a dose shown to be effective in CMV prevention in clinical trials.
This study demonstrates the safety and potential efficacy of low-dose valacyclovir for prevention of primary as well as secondary CMV reactivation in at-risk patients after allogeneic SCT. The study population is representative of the typical allogeneic SCT recipients. In fact, the patients included in this study were at a higher risk for CMV infection due to a significant percentage having GVHD requiring treatment with high-dose steroids. Supporting this contention is the proportion (66%) of patients developing secondary reactivation in the control group, which is higher than anticipated, based on other studies.
Although actual safety data were not obtained, valacyclovir appeared to be safe and well tolerated by most patients. The most frequent clinically observed side-effects were mild gastrointestinal consisting of nausea and vomiting. Side-effects pertaining to the central nervous system such as hallucinations and confusion, frequently encountered with higher doses of valacyclovir (6-8 g), were not observed in this patient population receiving lower doses of the drug. 16 Further studies will be required to document the safety of the drug in SCT patients.
This study did not demonstrate any difference in the incidence of CMV disease between the two groups. Although there was no significant difference in mortality associated with CMV disease between the two groups, there was a possible trend towards a lower death rate in the VG group although not statistically significant, especially in the patients receiving primary prophylaxis. This could be due to fewer infectious complications from neutropenia presumably induced by CMV infection and treatment with ganciclovir. Salzberger et al have reported higher infection rates with the prolonged use of ganciclovir. 21, 22 Although the small sample size in this study precludes definitive conclusions about the efficacy of valacyclovir for prevention of CMV reactivation in SCT patients, the results are very encouraging. Larger prospective randomized studies are needed to validate the efficacy suggested by the results of this retrospective study. Of further interest, the results suggest the efficacy and safety of valacyclovir given as 1 g three times a day. These results are comparable to the previously reported higher dose of the drug (6-8 g a day), which is associated with adverse effects on the central nervous system. It is also conceivable that slightly higher daily doses (4-5 g) than those used in this study could further improve efficacy without significantly increasing the toxicity. Dose evaluation should be part of further studies to determine both the safest and most effective dose in this patient population as well as timing of onset and duration of treatment with valacyclovir.
Recent studies have reported late-onset CMV disease in patients who received early ganciclovir prophylaxis up to 100 days after SCT. 3, 22 We did not observe late recrudescence of CMV in the patients of this study perhaps because valacyclovir was continued until immunosuppression was discontinued. Additional patient data and longer follow-up is needed to confirm this observation.
In conclusion, treatment with valacyclovir for the entire duration of risk of CMV infection after allogeneic SCT significantly reduced the risk of CMV infection with minimal side-effects. From these results and those in other immunosuppressive settings, it appears that use of valacyclovir is safe after SCT in conjunction with CMV surveillance and preemptive therapy for infection. Although the risk of CMV disease and associated mortality was not reduced, there was a trend towards lower non-CMV infectious complications. The use of valacyclovir for CMV prophylaxis also reduces the need for toxic preemptive therapy and its associated mortality and morbidity. The small sample size and retrospective design of the study are limitations of this study. The safe and effective use of valacyclovir in this study supports the need for a larger randomized study to validate these results.
